Chatham Capital Group Inc. lifted its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 15.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 72,370 shares of the exchange traded fund’s stock after buying an additional 9,680 shares during the quarter. SPDR S&P Biotech ETF comprises approximately 1.8% of Chatham Capital Group Inc.’s investment portfolio, making the stock its 17th largest holding. Chatham Capital Group Inc. owned about 0.14% of SPDR S&P Biotech ETF worth $6,265,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Wechter Feldman Wealth Management Inc. grew its position in shares of SPDR S&P Biotech ETF by 0.4% during the 2nd quarter. Wechter Feldman Wealth Management Inc. now owns 3,172 shares of the exchange traded fund’s stock worth $245,000 after buying an additional 12 shares during the period. Newman Dignan & Sheerar Inc. grew its position in shares of SPDR S&P Biotech ETF by 0.6% during the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 8,260 shares of the exchange traded fund’s stock worth $638,000 after buying an additional 50 shares during the period. Willingdon Wealth Management grew its position in shares of SPDR S&P Biotech ETF by 1.8% during the 2nd quarter. Willingdon Wealth Management now owns 6,541 shares of the exchange traded fund’s stock worth $505,000 after buying an additional 118 shares during the period. Bank of New York Mellon Corp grew its position in shares of SPDR S&P Biotech ETF by 1.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,274 shares of the exchange traded fund’s stock worth $1,488,000 after buying an additional 197 shares during the period. Finally, Vestor Capital LLC grew its position in shares of SPDR S&P Biotech ETF by 0.5% during the 2nd quarter. Vestor Capital LLC now owns 38,663 shares of the exchange traded fund’s stock worth $2,984,000 after buying an additional 208 shares during the period.

SPDR S&P Biotech ETF (XBI) traded down $0.56 during midday trading on Tuesday, reaching $80.87. 4,345,400 shares of the company traded hands, compared to its average volume of 4,232,969. SPDR S&P Biotech ETF has a twelve month low of $58.66 and a twelve month high of $88.98.

TRADEMARK VIOLATION WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/21/spdr-sp-biotech-etf-xbi-stake-increased-by-chatham-capital-group-inc.html.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Stock Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related stocks with our FREE daily email newsletter.